Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?

Since the patient has well-controlled extracranial disease, I would continue lurbinectedin. As the new intracranial lesions are potentially treatable with SRS, I would favor that approach for this patient.